Minjuvi® Receives Approval in Australia for Treating Relapsed Follicular Lymphoma

Minjuvi® Approved for Follicular Lymphoma in Australia

On April 23, 2026, the Therapeutic Goods Administration (TGA) in Australia approved Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide. This groundbreaking regimen is the first chemotherapy-free dual-targeted immunotherapy aimed at treating adults suffering from relapsed or refractory follicular lymphoma (R/R FL), a condition notorious for its difficulty in management and high recurrence rates.

Overview of Follicular Lymphoma

Follicular lymphoma is a type of non-Hodgkin lymphoma that constitutes around 20-30% of all NHL cases, making it the second most prevalent form. Approximately 1,500 new cases are diagnosed in Australia every year, and while many patients initially respond well to treatment, about 20% will experience a relapse within two years. Sadly, relapsed cases often lead to poorer long-term outcomes.

Professor Judith Trotman, a prominent lymphoma specialist, emphasizes the necessity for effective treatments that can extend the lives of patients with R/R FL since existing therapies sometimes fail to provide durable responses. The introduction of Minjuvi is considered a critical new option for these patients, aligning Australian therapeutic practices with global care standards.

In-depth Look at Minjuvi

Minjuvi combines tafasitamab—an engineered monoclonal antibody designed to target CD19 and CD20—with rituximab and lenalidomide. This combination was evaluated in the Phase 3 inMIND clinical trial, which included 652 participants, with 548 of them diagnosed with R/R FL. The Australian clinical landscape was bolstered by the participation of 54 locals across 12 trial sites.

The inMIND study revealed that patients receiving Minjuvi experienced a significant increase in progression-free survival (PFS), achieving a median PFS of 22.4 months compared to only 13.9 months for the control group. This translates to a remarkable 57% reduction in the risk of disease progression, relapse, or death.

In terms of safety, Minjuvi was generally well tolerated by patients. However, some common adverse reactions reported in over 20% of cases included respiratory infections, diarrhea, rash, fatigue, and musculoskeletal pain. Monitoring for infections is crucial, particularly due to the high incidence of bacterial and viral infections observed in the trial population.

The Importance of This Approval

The approval of Minjuvi marks a significant milestone, as this dual-targeted therapy addresses a gap in treatment for patients with a limited range of options following relapse. Carlo Montagner, the CEO of Specialised Therapeutics, expressed pride in bringing this chemotherapy-free therapy to Australians facing relapsed follicular lymphoma, reaffirming ST's commitment to improve care for this within the population.

Looking forward, ST plans to collaborate with Australia’s Pharmaceutical Benefits Advisory Committee and the Department of Health to ensure equitable access to Minjuvi for affected patients. The company has a history of navigating regulatory challenges effectively, as this represents their ninth success through the Project Orbis process since 2021.

This advancement is not just beneficial for the Australian population; it aligns with similar approvals in the U.S. and Europe, highlighting a global trend toward enhancing treatment options for lymphoma patients. Healthcare professionals in Australia can now discuss Minjuvi with eligible patients, marking a hopeful turning point for many battling this cancer.